Nicht steroidale Antirheumatika und gastrointestinales Risiko

Wolfgang W. Bolten

doi:10.1055/s-0043-116663

Aktuelle Rheumatologie, Table of Contents

Aktuelle Rheumatologie 2018; 43(01): 82-87
DOI: 10.1055/s-0043-116663

Übersichtsarbeit

Georg Thieme Verlag KG Stuttgart · New York

Nicht steroidale Antirheumatika und gastrointestinales Risiko

Non-Steroidal Anti-Inflammatory Drugs and Gastrointestinal Risk

Wolfgang W. Bolten

¹Innere Med., Rheumatologie, Klaus Miehlke-Klinik, Wiesbaden

› Author Affiliations

Abstract

Zusammenfassung

Bei somatischen muskuloskelettalen Schmerzerkrankungen werden nicht steroidale Antirheumatika (NSAR) mit Erfolg schmerz- und entzündungslindernd eingesetzt. Dazu hemmen sie die parakrine Synthese von Prostaglandinen (PG), die sowohl schmerzvermittelnd wirken, an anderer Stelle aber „house keeping“ Effekte haben. Dem Organismus stehen für die PG Synthese die Isoenzyme COX-1 und die induzierbare COX-2 zur Verfügung. Durch die Hemmung der COX-1 und konsekutiver Senkung der PG- Spiegel entstehen gastrointestinale Nebenwirkungen der GI-Mukosa. Im Gegensatz zu den traditionellen NSAR hemmen Coxibe selektiv die COX-2 und verursachen deshalb weniger GI-Probleme. Die Komedikation mit Protonenpumpenhemmern oder mit einem synthetischen PG-Analogon senkt die Ulkusrate ebenfalls. Auch andere nicht PG-abhängige Mechanismen schützen die Mukosa. Sie können ebenfalls durch NSAR gestört werden.

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) are used successfully to alleviate pain and inflammation in somatic musculoskeletal pain disorders. To this end, they inhibit the paracrine synthesis of prostaglandins (PGs), which induce pain while also having “house-keeping” effects. The COX-1 isoenzymes and the inducible COX-2 enzyme are available for PG synthesis in an organism. Inhibition of COX-1, followed by decreasing PG levels, leads to gastrointestinal side-effects affecting the GI mucosa. Unlike traditional NSAIDs, coxibs selectively inhibit COX-2, thereby causing fewer gastrointestinal problems. Co-medication with proton-pump inhibitors or a synthetic PG analogue also leads to a lower ulcer rate. Other non-PG-dependent mechanisms protect the mucosa. They also may be disrupted by NSAIDs.

Full Text

References

Literatur
1 Moore RA, Derry S, McQuay HJ. Topical agents in the treatment of rheumatic pain. Rheum Dis Clin North Am 2008; 34: 415-432
2 McQuay DM. RA An evidence-based resource for pain relief. Oxford: Oxford University Press; 1998
3 Richards D. The Oxford Pain Group League table of analgesic efficacy. Evid-Based Dentistry 2004; 5: 22-23
4 McQuay H, Moore A, Justins D. Treating acute pain in hospital. BMJ 1997; 314: 1531-1535
5 Towheed TE, Maxwell L, Judd MG. et al. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006; CD004257
6 Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093-2099
7 Lee SP, Sung IK, Kim JH. et al. Risk factors for the presence of symptoms in peptic ulcer disease. Clin Endosc 2016;
8 Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. NatNew Biol 1971; 231: 232-235
9 Yamamichi N, Shimamoto T, Sakaguchi Y. et al. Categorization of upper gastrointestinal symptoms is useful in predicting background factors and studying effects and usages of digestive drugs. PLoS One 2014; 9: e88277
10 Petruzzelli M, Vacca M, Moschetta A. et al. Intestinal mucosal damage caused by non-steroidal anti-inflammatory drugs: role of bile salts. Clin Biochem 2007; 40: 503-510
11 Sostres C, Gargallo CJ, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther 2013; 15 (Suppl. 03) S3
12 Lanas A, Boers M, Nuevo J. Gastrointestinal events in at-risk patients starting non-steroidal anti-inflammatory drugs (NSAIDs) for rheumatic diseases: the EVIDENCE study of European routine practice. Ann Rheum Dis 2015; 74: 675-681
13 Cardile S, Martinelli M, Barabino A. et al. Italian survey on non-steroidal anti-inflammatory drugs and gastrointestinal bleeding in children. World J Gastroenterol 2016; 22: 1877-1883
14 Lanas A, Sopena F. Nonsteroidal anti-inflammatory drugs and lower gastrointestinal complications. Gastroenterol Clin North Am 2009; 38: 333-+
15 Kvasnovsky CL, Aujla U, Bjarnason I. Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease. Scand J Gastroenterol 2015; 50: 255-263
16 Otani K, Tanigawa T, Watanabe T. et al. Microbiota plays a key role in non-steroidal anti-inflammatory drug-induced small intestinal damage. Digestion 2017; 95: 22-28
17 Mo C, Sun G, Wang YZ. et al. PPI versus histamine h2 receptor antagonists for prevention of upper gastrointestinal injury associated with low-dose aspirin: systematic review and meta-analysis. PLoS One 2015; 10: e0131558
18 Hsu PI, Tsai TJ. Epidemiology of upper gastrointestinal damage associated with low-dose aspirin. Curr Pharm Des 2015; 21: 5049-5055
19 Iijima K, Shimosegawa T. Risk factors for upper gi damage in low-dose aspirin users and the interaction between h. pylori infection and low-dose aspirin use. Curr Pharm Des 2015; 21: 5056-5065
20 Lanas A, Gargallo CJ. Management of low-dose aspirin and clopidogrel in clinical practice: a gastrointestinal perspective. J Gastroenterol 2015; 50: 626-637
21 Bombardier C, Laine L, Reicin A. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-1528
22 Bruno A, Tacconelli S, Patrignani P. Variability in the response to non-steroidal anti-inflammatory drugs: mechanisms and perspectives. Basic Clin Pharmacol Toxicol 2014; 114: 56-63
23 Tielemans MM, Eikendal T, Jansen JB. et al. Identification of NSAID users at risk for gastrointestinal complications: a systematic review of current guidelines and consensus agreements. Drug Saf 2010; 33: 443-453
24 Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 2037-2046
25 Singh G. Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System. AmJ Ther 2000; 7: 115-121
26 Singh G, Rosen Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective--1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol Suppl 1998; 51: 8-16
27 Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115: 787-796
28 Anglin R, Yuan Y, Moayyedi P. et al. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am J Gastroenterol 2014; 109: 811-819
29 Vandraas KF, Spigset O, Mahic M. et al. Non-steroidal anti-inflammatory drugs: use and co-treatment with potentially interacting medications in the elderly. Eur J Clin Pharmacol 2010; 66: 823-829
30 Dowell D, Kunins HV, Farley TA. Opioid analgesics--risky drugs, not risky patients. JAMA 2013; 309: 2219-2220
31 Gore M, Sadosky A, Leslie D. et al. Patterns of therapy switching, augmentation, and discontinuation after initiation of treatment with select medications in patients with osteoarthritis. Clin Ther 2011; 33: 1914-1931
32 Bolten WW, Kruger K, Reiter-Niesert S. et al. [DGRh recommendations for the implementation of current security aspects in the NSAID treatment of musculoskeletal pain]. Z Rheumatol 2016; 75: 103-116
33 Deng ZH, Zeng C, Yang Y. et al. Topical diclofenac therapy for osteoarthritis: a meta-analysis of randomized controlled trials. Clin Rheumatol 2016; 35: 1253-1261
34 Mozsik G. Capsaicin as new orally applicable gastroprotective and therapeutic drug alone or in combination with nonsteroidal anti-inflammatory drugs in healthy human subjects and in patients. Prog Drug Res 2014; 68: 209-258
35 Nissen SE, Yeomans ND, Solomon DH. et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 2016; 375: 2519-2529
36 Rahme E, Nedjar H. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rheumatology (Oxford) 2007; 46: 435-438
37 Chang C-H, Chen H-C, Lin J-W. et al. Risk of hospitalization for upper gastrointestinal adverse events associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study in Taiwan. Pharmacoepidemiology and Drug Safety 2011; 20: 763-771
38 Solomon DH, Rassen JA, Glynn RJ. et al. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med 2010; 170: 1968-1976
39 Jarupongprapa S, Ussavasodhi P, Katchamart W. Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis. J Gastroenterol 2013; 48: 830-838
40 Silverstein FE, Faich G, Goldstein JL. et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. Journal of the American Medical Association 2000; 284: 1247-1255
41 Laine L, Curtis SP, Cryer B. et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007; 369: 465-473
42 Schnitzer TJ, Burmester GR, Mysler E. et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364: 665-674
43 Chan FK, Lanas A, Scheiman J. et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376: 173-179
44 Silverstein FE, Graham DY, Senior JR. et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241-249
45 Vonkeman HE, van de Laar MA. Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention. Semin Arthritis Rheum 2010; 39: 294-312
46 Yeomans ND, Tulassay Z, Juhasz L. et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998; 338: 719-726
47 Lai KC, Chu KM, Hui WM. et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 2005; 118: 1271-1278
48 Chan FK, Wong VW, Suen BY. et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007; 369: 1621-1626
49 Chan FK, Hung LC, Suen BY. et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 2004; 127: 1038-1043
50 Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. The Lancet 2013; 382: 769-779
51 Hawkey CJ, Karrasch JA, Szczepanski L. et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998; 338: 727-734
52 Bianchi Porro G, Lazzaroni M, Manzionna G. et al. Omeprazole and sucralfate in the treatment of NSAID-induced gastric and duodenal ulcer. Aliment Pharmacol Ther 1998; 12: 355-360